$BDTX News
Last published 1d ago
- 1d agoBDTXSTIFEL 2026 HEALTHCARE CONFERENCE - BLACK DIAMOND THERAPEUTICS INCEarnings Call TranscriptsAll right. So I'm here with Black Diamond Therapeutics CEO, Mark. So Mark, anything new today? Lots new today. Really great to be here at the Stifel Conference after disclosing new data from our phase two trial and a rea
- 1d agoBDTXQ4 2026 Silevertinib Program Update Webcast - BLACK DIAMOND THERAPEUTICS INCEarnings Call TranscriptsGood morning and thank you for standing by. Welcome to the Celebratinib program update webcast. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answe
- 1d agoBDTXBlack Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate UpdateGlobeNewswireUpdated Phase 2 results demonstrate robust CNS activity, including 86% CNS-ORR and mPFS double that of currently available EGFR TKIs, in patients with untreated brain metastasesRecent End-of-Phase 2 meeting with the FDA
- 1d agoBDTXBlack Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate UpdateGlobeNewswireCAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today reported updated data from its Phase 2 tri ...
- 1d agoBDTXBlack Diamond Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoBDTXBlack Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLCGlobeNewswireWebcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET
- 2d agoBDTXBlack Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLCGlobeNewswireWebcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing
- 2mo agoBDTXBlack Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in
- 3mo agoBDTXBlack Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswirePresented positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC at the 2026 ASCO Annual Meeting, including that no patients developed de novo brain metastases and that patients
- 5mo agoBDTXJefferies Global Healthcare Conference in New York - BLACK DIAMOND THERAPEUTICS INCEarnings Call TranscriptsHello, everyone. My name is Farzin Haque, one of the biotech analysts at Jefferies. It's my pleasure to introduce Mark Veleka, CEO of Black Diamond Therapeutics. This is a fireside chat format. Thank you for joining us t
- 5mo agoBDTXBlack Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in
- 5mo agoBDTXBlack Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical MutationsGlobeNewswirePreliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastasesORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACCDose dependent
- 5mo agoBDTXBlack Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLCGlobeNewswireWebcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey
- 6mo agoBDTXBlack Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireOral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual MeetingFirst patient dosed in the Phase 2 trial of
- 6mo agoBDTXBlack Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual MeetingGlobeNewswirePoster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed
- 7mo agoBDTX25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE - BLACK DIAMOND THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, everyone. Welcome to the next session with Black Diamond Therapeutics. I'm Amit Fadia, biogec analyst here at Needham. It's my pleasure to be hosting Elizabeth Buck, who is the chief scientific officer at
- 8mo agoBDTXBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireClinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, including preliminary DOR and PFS data in frontline settingCompany is preparing to initiate a randomized
- 8mo agoBDTXBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in
- 9mo agoAVBPSMMTMRUSMRK+9EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsightPR NewswireDelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs,...
- 11mo agoBDTXBlack Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBMGlobeNewswireSilevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals
- 11mo agoBDTXBlack Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program UpdateGlobeNewswireWebcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey
- 1y agoBDTXBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in
- 1y agoBDTXBlack Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireORR and preliminary duration of treatment data for the Phase 2 trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter Cash, cash equivalents, and investments of $135.5 million as of
- 1y agoBDTXBlack Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireEnrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025Exploring partnership opportunities to advance
- 1y agoBDTXBlack Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in
- 1y agoBDTXBlack Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireClinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR
- 1y agoBDTXBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in
- 1y agoBDTXServier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology TherapyGlobeNewswireThe partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential
- 1y agoBDTXBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswireClinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored "window of opportunity" trial into newly diagnosed glioblastoma patients
- 1y agoBDTXKYMRNAYANAYA Biosciences Announces Nomination of New Board MembersGlobeNewswireNew board reflects company's added focus on oncology & autoimmune diseases SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences ("NAYA") (NASDAQ:NAYA), a life science portfolio company
- 2y agoBDTXBlack Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireAnnounced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 Presented real-world
- 2y agoBDTXBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in
- 2y agoBDTXBlack Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash RunwayGlobeNewswireCompany advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into Q2 2026
- 2y agoBDTXBlack Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance MutationsGlobeNewswireBDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed Preliminary ORR of 42% in 19 patients at 200 mg with on-target resistance EGFR mutations
- 2y agoBDTXBlack Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLCGlobeNewswireWebcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey
- 2y agoBDTXBlack Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024GlobeNewswireTreatment data were analyzed from 3,276 cases of patients with newly diagnosed EGFR mutant NSCLC from Guardant Health Analyses of patients with non-classical EGFR mutations reveal that the majority receive frontline
- 2y agoBDTXGYREGyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of DirectorsGlobeNewswireSAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic
- 2y agoBDTXBlack Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireInitial Phase 2 data of BDTX-1535 in 2L/3L patients with EGFRm NSCLC on track for later in Q3 2024On track to announce initial Phase 2 data of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC in Q1 2025, and
- 2y agoBDTXBlack Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireResults from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase
- 2y agoBDTXBlack Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in
- 2y agoBDTXBlack Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireInitial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data expected Q1 2025Presented
- 2y agoBDTXBlack Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireCAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in
- 2y agoADAPBDTXDVASTOKGarry Menzel joins GHO Capital as Operating PartnerGlobeNewswireGarry Menzel joins GHO Capital as Operating Partner Former CEO of TCR² Therapeutics with significant investment and operating experience to support deal origination and provide best in class services to pioneering
- 2y agoBDTXBlack Diamond Therapeutics Announces Changes to Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in
- 2y agoBDTXBlack Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual MeetingGlobeNewswireReal-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting
- 2y agoBDTXBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
- 2y agoBDTXBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswireDosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired resistance or non-classical
- 2y agoBDTXBlack Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024GlobeNewswireCAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in
- 2y agoBDTXBlack Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in
- 2y agoBDTXBlack Diamond Therapeutics Announces Corporate Update and Expected 2024 MilestonesGlobeNewswireFDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track Designation granted for BDTX-1535 as second-line treatment for EGFR mutant/C797S NSCLC